Table 2.

Duration of gold treatment and concomitant disease-modifying antirheumatic drugs (DMARD) received during gold treatment.

Drug TreatmentNo. (%)
Gold duration (mo) at last visit in 2009, n = 71*
  ≥ 525 (35)
  6 to 1014 (20)
  11 to 2022 (31)
  ≥ 2010 (14)
Concomitant DMARD, n = 71*
  None12 (17)
  1 DMARD36 (51)
  2 DMARD18 (25)
  3 DMARD2 (3)
  1 biologic1 (1)
  ≥ 1 DMARD + biologic2 (2)
Concomitant gold/DMARD combinations, n = 71*
  Gold alone12 (17)
  Gold + MTX11 (15)
  Gold + HCQ20 (28)
  Gold + SSZ3 (4)
  Gold + CyA2 (3)
  Gold + anti-TNF1 (1)
  Gold + MTX + HCQ12 (17)
  Gold + MTX + SSZ2 (3)
  Gold + MTX + LEF1 (1)
  Gold + MTX + anti-TNF2 (3)
  Gold + HCQ + SSZ3 (4)
  Gold + MTX + chloroquine + LEF1 (1)
  Gold + MTX + HCQ + SSZ1 (1)
  • * Counts and percentages based on available data. Ten patients never started gold and thus disease duration and age at time of admission to clinic were not applicable. MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; CyA: cyclosporin A; anti-TNF: anti-tumor necrosis factor (includes etanercept, adalimumab, and/or infliximab); LEF: leflunomide.